^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Urothelial Cancer
    Drug:Tevimbra (tislelizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    BeiGene Press Release
    Title:

    China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

    Published date:
    04/10/2020
    Excerpt:
    ...anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Sci
    Title:

    Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

    Published date:
    11/06/2020
    Excerpt:
    ...efficacy of tislelizumab 200 mg administered intravenously Q3W in patients with locally advanced or metastatic PD‐L1+ UC who progressed during or following platinum‐containing therapy….Figure 4…ORR was found to be 29.4% in patients with PD-L1 >/= 50%
    DOI:
    10.1111/cas.14681
    Trial ID:
    RATIONALE-204